Shah et al. reported that HER2+ subtype of breast cancer is associated with gene amplification and/or protein overexpression of ERBB2, which leads to aggressive tumor growth and poor clinical outcome (Arora et al., 2008; Shah and Osipo, 2016). This evidence concerns the gene ERBB2 and breast carcinoma.